Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 279

1.

[Thalidomide in treatment of connective diseases and vasculities].

Maruotti N, Cantatore FP, Ribatti D.

Reumatismo. 2006 Jul-Sep;58(3):187-90. Review. Italian.

2.

Thalidomide: focus on its employment in rheumatologic diseases.

Ossandon A, Cassarà EA, Priori R, Valesini G.

Clin Exp Rheumatol. 2002 Sep-Oct;20(5):709-18. Review.

PMID:
12412207
3.

[Thalidomide: the revival].

Grosbois B, Duguet C.

Rev Med Interne. 2001 Jan;22(1):5-7. French. No abstract available.

PMID:
11218298
4.

[Thalidomide: new uses for an old drug].

Wu KL, Sonneveld P.

Ned Tijdschr Geneeskd. 2002 Aug 3;146(31):1438-41. Review. Dutch.

PMID:
12190008
5.

Thalidomide: current and potential clinical applications.

Calabrese L, Fleischer AB.

Am J Med. 2000 Apr 15;108(6):487-95. Review.

PMID:
10781782
6.

Dermatologic and nondermatologic uses of thalidomide.

Nasca MR, Micali G, Cheigh NH, West LE, West DP.

Ann Pharmacother. 2003 Sep;37(9):1307-20. Review.

PMID:
12921515
7.

The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide.

Strupp C, Germing U, Aivado M, Kündgen A, Fenk R, Hünerlitürkoglu A, Kobbe G, Haas R, Gattermann N.

Leuk Lymphoma. 2005 Jul;46(7):999-1006.

PMID:
16019550
8.

Thalidomide has both anti-inflammatory and regulatory effects in Behcet's disease.

Direskeneli H, Ergun T, Yavuz S, Hamuryudan V, Eksioglu-Demiralp E.

Clin Rheumatol. 2008 Mar;27(3):373-5. Epub 2007 Nov 23.

PMID:
18034203
9.

Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus.

Walchner M, Meurer M, Plewig G, Messer G.

Int J Dermatol. 2000 May;39(5):383-8.

PMID:
10849134
10.

Thalidomide: a remarkable comeback.

Jacobson JM.

Expert Opin Pharmacother. 2000 May;1(4):849-63. Review.

PMID:
11249521
11.

Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.

Breitkreutz I, Anderson KC.

Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):973-85. doi: 10.1517/17425255.4.7.973 . Review.

PMID:
18624684
12.

Thalidomide in Behçet's disease.

Shek LP, Lim DL.

Biomed Pharmacother. 2002 Feb;56(1):31-5. Review.

PMID:
11908493
13.

Adverse effects of thalidomide administration in patients with neoplastic diseases.

Dimopoulos MA, Eleutherakis-Papaiakovou V.

Am J Med. 2004 Oct 1;117(7):508-15. Review.

PMID:
15464708
14.

Theoretical basis for the activity of thalidomide.

Meierhofer C, Dunzendorfer S, Wiedermann CJ.

BioDrugs. 2001;15(10):681-703. Review.

PMID:
11604049
15.

Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients.

Coelho A, Souto MI, Cardoso CR, Salgado DR, Schmal TR, Waddington Cruz M, de Souza Papi JA.

Lupus. 2005;14(6):434-9.

PMID:
16038106
16.

Thalidomide: an antineoplastic agent.

Amato RJ.

Curr Oncol Rep. 2002 Jan;4(1):56-62. Review.

PMID:
11734114
18.
19.

[Thalidomide and thrombosis: three observations].

Pouaha J, Martin S, Trechot P, Truchetet F, Barbaud A, Schmutz JL.

Presse Med. 2001 Jun 9;30(20):1008-9. French. No abstract available.

PMID:
11433688
20.

Thalidomide in gastrointestinal disorders.

Bousvaros A, Mueller B.

Drugs. 2001;61(6):777-87. Review.

PMID:
11398909
Items per page

Supplemental Content

Write to the Help Desk